Navigation Links
/C O R R E C T I O N -- Agendia B.V./
Date:6/26/2009

In the news release, "Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations" issued on 23 Jun 2009 12:00 GMT, by Agendia B.V. over PR Newswire, please be advised that the subheadline was missing from the release as incorrectly transmitted by PR Newswire. Complete, corrected release follows:

, /PRNewswire/ --

Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations - International Expert Panel Recommends Use of Multigene Profiling Assays and Finds Intermediate Scores Lack Clinical Utility

HUNTINGTON BEACH, California and AMSTERDAM, June 23 2009 - Agendia, a world leader in molecular cancer diagnostics, today announced the inclusion of its breast cancer recurrence test MammaPrint in St. Gallen's 2009 International Expert Consensus on the primary therapy of early breast cancer. The recommendations have been published online in the Annals of Oncology and will appear in the August print edition.

The St. Gallen expert panel consists of key opinion leaders from across Europe (53%), the United States (33%), and rest of the world (14%). In the recently published article highlighting the 2009 recommendations, the panellists emphasize that "in an important change from the previous St. Gallen conference...the Panel supported the use of a validated multigene- profiling assay, if readily available, as an adjunct to high-quality phenotyping of breast cancer in cases in which the indication for adjuvant chemotherapy remained uncertain."

In addition, the panel cautioned that so-called intermediate scores are not useful in clinical decision making. Currently, MammaPrint is the only breast cancer recurrence assay available that accurately yields a binary result, without an intermediate group, addressing the panel's recommendations. The FDA-cleared a ssay is always clinically useful and indicates whether a patient is at low or high risk for metastasis and the resulting clarity is vital in helping physicians personalize treatment options.

"St. Gallen's guideline inclusion is a key step in further establishing MammaPrint as a standard of care. It also supports our commitment to upholding rigorous standards of quality and efficacy," said Dr. Bernhard Sixt, Agendia's President and Chief Executive Officer. "With MammaPrint we aim to provide breast cancer patients and their physicians with definitive answers to crucial treatment questions."

In addition to MammaPrint, the company also offers TargetPrint to further improve breast cancer treatment options. TargetPrint quantitatively determines the gene expression levels of HER2neu, estrogen and progesterone receptors. Ongoing research and development efforts continue to augment Agendia's ability to accurately predict breast cancer recurrence, and help physicians tailor individual treatment plans to their patients.

    For online access to the Annals of Oncology:
http://annonc.oxfordjournals.org/cgi/content/full/mdp322v1

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatment within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer therapy. The company markets four products, with several new genomic tests in development. Agendia collaborates with pharmaceutical companies in the development of highly effective personalized drugs in the area of oncology and was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based i n Huntington Beach, California, and in Amsterdam, The Netherlands. For more information please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
2. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
3. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
4. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
5. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
6. Agendia Launches TargetPrint(R) for Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 According to ... Growth and Demand Forecast to 2022 - Industry Insights by ... Diagnostic Center and Others)" by P&S Market Research, the global ... in 2015, and it is expected to grow at a ... high slice type segment is expected to witness the faster ...
(Date:5/4/2016)... D.C. , May 4, 2016 ... member companies concluded a series of free workshops ... in global requirements for Good Distribution ... of quality assurance which ensures that products are consistently stored, ... the marketing authorization (MA) or product specification. Only a ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Multiple Myeloma ...  report to their offering.       ... Multiple Myeloma Market and Competitive Landscape Highlights ... pipeline products, Multiple Myeloma epidemiology, Multiple Myeloma ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Sun Health registered ... the organization’s successful Care Transitions program at the 9th Annual Orthopedic ... “Minimizing Costs in the Post-Acute Environment Through Effective Transitions of Care.” , Major ...
(Date:5/5/2016)... Diego, CA (PRWEB) , ... May 05, 2016 , ... ... travel nursing firm, is encouraging people all over the United States to thank a ... May 12, Aya Healthcare will donate $5 to the American Red Cross of San ...
(Date:5/5/2016)... Ohio (PRWEB) , ... May 05, 2016 , ... United ... Cycle. , Clark brings more than 15 years of experience within the healthcare ... from a successful career as the Director of Patient Financial Services at Spectrum Health. ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... for iOS and Android devices. VisualDx is the first point of care ... support across general medicine. The system speeds diagnosis, therapy decisions and patient ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... With May flowers, summer is just around ... it means a welcome respite from school and the ability to play all day and ... for their children or watch the little tykes themselves. Summer also means trips to the ...
Breaking Medicine News(10 mins):